Maravai (MRVI) director Mihas receives 46,293 RSUs held for GTCR-affiliated entity
Rhea-AI Filing Summary
MIHAS CONSTANTINE S reported acquisition or exercise transactions in this Form 4 filing.
Maravai LifeSciences Holdings, Inc. director Constantine S. Mihas reported receiving a grant of 46,293 restricted stock units tied to Class A common stock at no cost on May 26, 2026. The award was made under the company’s 2020 Omnibus Incentive Plan and vests in full on the earlier of one year from grant or the 2027 annual stockholders’ meeting.
According to the disclosure, Mihas holds these securities for the benefit of a GTCR‑affiliated entity under its policies and disclaims any pecuniary interest or beneficial ownership for Section 16 purposes. Following this award, 184,348 shares or units are reported as held on behalf of the GTCR‑affiliated entity.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 46,293 shares
Net Buy
1 txn
Insider
MIHAS CONSTANTINE S
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Class A Common Stock | 46,293 | $0.00 | $0.00 |
Holdings After Transaction:
Class A Common Stock — 184,348 shares (Direct)
Footnotes (2)
- F1. Represents restricted stock units awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan on May 26, 2026, which vest in full upon the earlier of one year from the date of grant or the date of the 2027 Maravai LifeSciences Holdings, Inc. annual meeting of stockholders.
- F2. The Reporting Person holds these securities of the Issuer for the benefit of a GTCR-affiliated entity. Pursuant to the policies of the GTCR-affiliated entities, the Reporting Person must hold the securities on behalf of and for the benefit of the GTCR-affiliated entity. The Reporting Person disclaims any pecuniary interest in the securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16.
Key Figures
RSUs granted: 46,293 restricted stock units
Post-transaction holdings: 184,348 shares/units
Vesting condition: Earlier of 1 year or 2027 annual meeting
3 metrics
RSUs granted
46,293 restricted stock units
Award of Class A Common Stock units on May 26, 2026
Post-transaction holdings
184,348 shares/units
Total Class A position reported after the grant
Vesting condition
Earlier of 1 year or 2027 annual meeting
Full vesting schedule for the 46,293 RSUs
Key Terms
restricted stock units, 2020 Omnibus Incentive Plan, pecuniary interest, beneficial owner, +1 more
5 terms
restricted stock units financial
"Represents restricted stock units awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
2020 Omnibus Incentive Plan financial
"awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan on May 26, 2026"
pecuniary interest financial
"The Reporting Person disclaims any pecuniary interest in the securities"
beneficial owner financial
"shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities"
A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.
Section 16 regulatory
"beneficial owner of the securities for purposes of Section 16"
Section 16 is a U.S. securities law rule that governs the trading and disclosure obligations of company insiders — typically officers, directors and large shareholders — to promote transparency and deter unfair profit-taking. It requires insiders to publicly report their stock trades and allows companies or the issuer to reclaim quick, short-term profits from certain insider trades, like a scoreboard and a refund policy that help investors see and limit possible insider advantage.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did Maravai LifeSciences (MRVI) report for Constantine Mihas?
Maravai LifeSciences reported that director Constantine S. Mihas received 46,293 restricted stock units of Class A common stock at no cost as an equity award. The grant is compensation-related, not an open-market trade, and was made under the company’s 2020 Omnibus Incentive Plan.
When do Constantine Mihas’s 46,293 Maravai (MRVI) restricted stock units vest?
The 46,293 restricted stock units vest in full on the earlier of one year from the May 26, 2026 grant date or the date of Maravai LifeSciences’ 2027 annual meeting of stockholders. This single-vesting schedule links the award to continued board service or that meeting date.
Was Constantine Mihas’s Maravai (MRVI) equity grant an open-market purchase or sale?
The transaction is coded as a grant or award with zero price per share, indicating a compensation-related acquisition, not an open-market buy or sell. It represents restricted stock units awarded under the company’s 2020 Omnibus Incentive Plan rather than trading in the market.